1
|
Matrone F, Furlan C, Rupolo M, Ciancia R, Zanet E, Montante B, Navarria F, Palazzari E, Farina E, Bulian P, Mascarin M, De Paoli A, Franchin G, Michieli M. EP-1246: Radiotherapy after autologous stem cell transplant in recurrent or refractory hodgkin's lymphoma. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31556-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
2
|
Berretta M, Zanet E, Di Benedetto F, Simonelli C, Bearz A, Morra A, Bonanno S, Berretta S, Tirelli U. Unusual Presentation of Metastatic Hepatocellular Carcinoma in an HIV/HCV Coinfected Patient: Case Report and Review of the Literature. Tumori 2018; 94:589-91. [DOI: 10.1177/030089160809400424] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Hepatocellular carcinoma (HCC) is an increasing cause of mortality in human immunodeficiency virus (HIV) seropositive patients. Concurrent infection with HIV may accelerate the progression from cirrhosis to HCC. Viral hepatitis and alcohol abuse are the main risk factors for HCC in developed countries. Exposure to these risk factors is common among HIV-infected patients. We report the case of a 43-year-old woman affected by HCC, with unusual soft tissue metastases (left masseter muscle) and HIV/HCV coinfection. The usual route of metastatic spread from classic HCC is hematogenous, with the most common extrahepatic site being the lung. Our case, besides the unusual distant metastatic site, showed very rapid clinical progression, as has been commonly observed in HIV-infected patients with HCC. The case series of HCC in HIV-positive individuals published to date does not cumulatively exceed 70 subjects.
Collapse
Affiliation(s)
| | - Ernesto Zanet
- Division of Medical Oncology A, National Cancer Institute, Aviano
| | - Fabrizio Di Benedetto
- Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena
| | | | - Alessandra Bearz
- Division of Medical Oncology A, National Cancer Institute, Aviano
| | - Aldo Morra
- Radiology Unit, National Cancer Institute, Aviano
| | - Santo Bonanno
- Department of Surgery, University of Catania, Catania, Italy
| | | | - Umberto Tirelli
- Division of Medical Oncology A, National Cancer Institute, Aviano
| |
Collapse
|
3
|
Zanet E, Ciancia R, Michieli M, Tirelli U. "Twistin' the night away": Fertility preservation in young adult female cancer survivors. Cancer 2017; 123:707-708. [PMID: 27727453 DOI: 10.1002/cncr.30394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Accepted: 09/07/2016] [Indexed: 11/07/2022]
Affiliation(s)
- Ernesto Zanet
- Unit of Cell Therapy and High Dose Chemotherapy CRO Aviano National Cancer Institute, Aviano, Italy
| | - Rosanna Ciancia
- Unit of Cell Therapy and High Dose Chemotherapy CRO Aviano National Cancer Institute, Aviano, Italy
| | - Mariagrazia Michieli
- Unit of Cell Therapy and High Dose Chemotherapy CRO Aviano National Cancer Institute, Aviano, Italy
| | - Umberto Tirelli
- Division of Medical Oncology A CRO Aviano National Cancer Institute, Aviano, Italy
| |
Collapse
|
4
|
Zanet E, Balsalobre P, Taborelli M, Diez-Martin J, Re A, Ribera JM, Rupolo M, Genet P, Serraino D, Guillerm G, Mazzucato M, Durante C, Gabriel I, Cwynarski K, Conde Garcia E, Varela Gomez MR, Ciancia R, Tirelli U, Michieli M. Post-transplantation long-term outcomes in 43 HIV-positive patients affected by high-risk or relapsed lymphoma. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.5_suppl.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
121 Background: The advent of highly active antiretroviral therapy (HAART) allowed to extend autologous stem cell transplantation (ASCT) to HIV-positive patients affected by lymphoma. In the literature, data are lacking on long-term events developed by this population. Methods: Herein we are reporting the preliminary analysis of long-term data of 43 pts out of 61 pts, affected by high-risk or relapsed lymphoma and treated by ASCT in different European countries. These 61 pts reached a complete response after ASCT and received HAART concomitantly to chemotherapy. We considered the following events after ASCT: lymphoma relapses, second cancers, opportunistic infections (OIs) and cardiovascular events. Results: Thirteen pts experienced OIs, after 0.36 years from ASCT (IQR: 0.12 -2.91). Twelve pts had a secondary malignancy and 6 pts had a lymphoma relapse, at a median time of 4.90 years (IQR: 2.56 – 9.90) and 2.88 years (IQR: 0.57 – 4.27) from ASCT, respectively. Six pts developed a cardiovascular event at 6.29 years (IQR: 4.84 – 9.32) from ASCT. Eight pts died: 3 of lymphoma relapse, 3 of second malignancy, 1 of acute myocardial infarction and 1 of car accident. With a median of 9.18 years of follow-up, (IQR: 5.99-12.43) the OS, PFS and EFS of the entire sample of pts were 82%, 75% and 35% at 10 years, respectively. Conclusions: Thirty-five out of 43 pts are still alive and in long-term complete remission after ASCT. These data confirm the long-term dramatic efficacy of ASCT. We support surveillance of OIs early after ASCT and of second cancers, lymphoma relapses and cardiovascular events from ASCT. Secondary malignancies developed by our pts are non-AIDS-defining cancers and a majority are linked to a viral pathogenesis or lifestyle behaviours (i.e. smoking). Secondary cancers and lymphoma relapses are the main causes of death in this population. Cardiovascular events may represent a cause of death but also a major reason of disability.
Collapse
Affiliation(s)
| | | | | | | | | | - Josep M. Ribera
- ICO-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, UAB, Badalona, Spain
| | | | | | | | | | | | | | - Ian Gabriel
- Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
5
|
Zanet E, Michieli M, Tirelli U. Autologous stem cell transplantation in HIV-positive patients affected by relapsed/partially responding lymphoma: let it be. Expert Rev Hematol 2016; 9:617-9. [PMID: 27269371 DOI: 10.1080/17474086.2016.1194751] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Ernesto Zanet
- a Unit of Cell Therapy and High Dose Chemotherapy , CRO National Cancer Institute , Aviano , Italy
| | - Mariagrazia Michieli
- a Unit of Cell Therapy and High Dose Chemotherapy , CRO National Cancer Institute , Aviano , Italy
| | - Umberto Tirelli
- b Division of Medical Oncology A , CRO National Cancer Institute , Aviano , Italy
| |
Collapse
|
6
|
Tirelli U, Zanet E, Spina M, Michieli M. Cancer survivorship: Is there a role for cancer survivor clinics? J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.3_suppl.e272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e272 Background: The population of survivors of cancer is increasing worldwide. In Italy, 2,243,953 patients (4% of the Italian population) survived after a cancer diagnosis in 2006. The drafting of survivorship care plans (SCPs), consisting of a written treatment summary and a follow-up care plan, is regarded by both the Institute of Medicine and the American Society of Clinical Oncology as an essential step in the care of survivors of cancer. However, Salz et al. in 2013 reported in Cancer that although oncology providers have positive feelings regarding SCPs, only 52% of them ever provided any component of an SCP to their patients. Ultimately, the lack of integration of SCPs into clinical practice is due to the absence of definite guidance regarding what constitutes standards of care for survivors of cancer. Methods: We propose the establishment of cancer survivor clinics (CSCs), which consist of health professionals (i.e., medical oncologists; radiation therapists; psychologists; nurses; and other physicians such as cardiologists, gynecologists, and urologists) dedicated to the care of survivors of cancer who we have previously defined as disease and treatment free for at least 5 years and that is established within our Institution since 2013. Results: The number of these CSCs should be planned in relation to the estimated number of survivors of cancer in each country and designed within the medical oncology departments. Conclusions: CSCs should assess: 1) the occurrence of any known side effects from cancer or its treatment (i.e., neurocognitive problems, premature menopause, infertility, cardiorespiratory system dysfunctions, and chronic fatigue); 2) the concomitant presence of comorbidities and their influence on the patient’s general health status; 3) psychological disturbances (i.e., fear of cancer recurrence, anxiety, depression, and body image perception disorders); and 4) problems regarding social and employment reintegration. Moreover, CSCs should provide screening guidelines for cancer recurrence and second primary tumors, design proper clinical follow-up pathways, promote behavioral changes (i.e., smoking cessation and alcohol intake reduction), and improve screening and prevention programs for the relatives of cancer survivors.
Collapse
|
7
|
Zanet E, Michieli M, Tirelli U. The long and winding road in cancer survivorship care. Cancer 2015; 121:3748-9. [PMID: 26137995 DOI: 10.1002/cncr.29545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Accepted: 06/05/2015] [Indexed: 11/06/2022]
Affiliation(s)
- Ernesto Zanet
- Unit of Cell Therapy and High Dose Chemotherapy, Centro di Riferimento Oncologico (CRO) Aviano National Cancer Institute, Aviano, Italy
| | - Mariagrazia Michieli
- Unit of Cell Therapy and High Dose Chemotherapy, Centro di Riferimento Oncologico (CRO) Aviano National Cancer Institute, Aviano, Italy
| | - Umberto Tirelli
- Division of Medical Oncology A, Centro di Riferimento Oncologico (CRO) Aviano National Cancer Institute, Aviano, Italy
| |
Collapse
|
8
|
Zanet E, Durante C, Rupolo M, Mazzucato M, Zanussi S, De Paoli P, Lleshi A, Taborelli M, Serraino D, Tirelli U, Spina M, Michieli M. Post-transplantation long-term events in a cohort of HIV-positive patients affected by relapsed/refractory lymphoma. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.7031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | - Arben Lleshi
- National Cancer Institute CRO Aviano, Aviano, Italy
| | | | | | | | | | | |
Collapse
|
9
|
Pratesi C, Zanussi S, Tedeschi R, Bortolin MT, Talamini R, Rupolo M, Scaini C, Basaglia G, Di Maso M, Mazzucato M, Zanet E, Tirelli U, Michieli M, Carbone A, De Paoli P. γ-Herpesvirus load as surrogate marker of early death in HIV-1 lymphoma patients submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation. PLoS One 2015; 10:e0116887. [PMID: 25668032 PMCID: PMC4323102 DOI: 10.1371/journal.pone.0116887] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Accepted: 12/16/2014] [Indexed: 12/13/2022] Open
Abstract
Autologous stem cell transplantation (ASCT) is a feasible procedure for human immunodeficiency virus-1 (HIV-1) lymphoma patients, whose underlying disease and intrinsic HIV-1- and ASCT-associated immunodeficiency might increase the risk for γ-herpesvirus load persistence and/or reactivation. We evaluated this hypothesis by investigating the levels of Epstein-Barr virus (EBV)- and Kaposi sarcoma-associated herpesvirus (KSHV)-DNA levels in the peripheral blood of 22 HIV-1-associated lymphoma patients during ASCT, highlighting their relationship with γ-herpesvirus lymphoma status, immunological parameters, and clinical events. EBV-DNA was detected in the pre-treatment plasma and peripheral blood mononuclear cells (PBMCs) of 12 (median 12135 copies/mL) and 18 patients (median 417 copies/106 PBMCs), respectively; the values in the two compartments were correlated (r = 0.77, p = 0.0001). Only EBV-positive lymphomas showed detectable levels of plasma EBV-DNA. After debulking chemotherapy, plasma EBV-DNA was associated with lymphoma chemosensitivity (p = 0.03) and a significant higher mortality risk by multivariate Cox analysis adjusted for EBV-lymphoma status (HR, 10.46, 95% CI, 1.11–98.32, p = 0.04). After infusion, EBV-DNA was detectable in five EBV-positive lymphoma patients who died within six months. KSHV-DNA load was positive in only one patient, who died from primary effusion lymphoma. Fluctuations in levels of KSHV-DNA reflected the patient’s therapy and evolution of his underlying lymphoma. Other γ-herpesvirus-associated malignancies, such as multicentric Castleman disease and Kaposi sarcoma, or end-organ complications after salvage treatment were not found. Overall, these findings suggest a prognostic and predictive value of EBV-DNA and KSHV-DNA, the monitoring of which could be a simple, complementary tool for the management of γ-herpesvirus-positive lymphomas in HIV-1 patients submitted to ASCT.
Collapse
Affiliation(s)
- Chiara Pratesi
- Microbiology, Immunology and Virology Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Stefania Zanussi
- Microbiology, Immunology and Virology Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
- * E-mail:
| | - Rosamaria Tedeschi
- Microbiology, Immunology and Virology Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Maria Teresa Bortolin
- Microbiology, Immunology and Virology Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Renato Talamini
- Epidemiology and Biostatistics Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Maurizio Rupolo
- Cellular Therapy and High-Dose Chemotherapy Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Chiara Scaini
- Microbiology, Immunology and Virology Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Giancarlo Basaglia
- Microbiology, Immunology and Virology Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Matteo Di Maso
- Epidemiology and Biostatistics Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Mario Mazzucato
- Stem Cell Collection and Processing Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Ernesto Zanet
- Cellular Therapy and High-Dose Chemotherapy Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Umberto Tirelli
- Division of Medical Oncology A, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Mariagrazia Michieli
- Cellular Therapy and High-Dose Chemotherapy Unit, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Antonino Carbone
- Department of Pathology, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| | - Paolo De Paoli
- Scientific Directorate; CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
| |
Collapse
|
10
|
Affiliation(s)
- Ernesto Zanet
- Centro di Riferimento Oncologico Aviano National Cancer Institute, Aviano, Italy
| | - Mariagrazia Michieli
- Centro di Riferimento Oncologico Aviano National Cancer Institute, Aviano, Italy
| | - Umberto Tirelli
- Centro di Riferimento Oncologico Aviano National Cancer Institute, Aviano, Italy
| |
Collapse
|
11
|
Zanet E, Michieli M, Tirelli U. Reply to long-term survivorship clinics led by primary care physicians within the cancer center may be a good option for coordinated survivorship care. Cancer 2014; 120:3753-4. [PMID: 25060905 DOI: 10.1002/cncr.28941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Accepted: 07/02/2014] [Indexed: 11/10/2022]
Affiliation(s)
- Ernesto Zanet
- Unit of Cell Therapy and High Dose Chemotherapy, Centro di Riferimento Oncologico (CRO) Aviano National Cancer Institute, Aviano, Italy
| | | | | |
Collapse
|
12
|
Affiliation(s)
- Ernesto Zanet
- Unit of Cell Therapy and High Dose Chemotherapy, Centro di Riferimento Oncologico (CRO) Aviano National Cancer Institute, Aviano, Italy
| | | | | |
Collapse
|
13
|
Pup LD, Zanet E, Rupolo M, Talamini R, Tirelli U, Mazzucato M, Steffan A, Zanussi S, Doretto P, Michieli M. Which tools may help physicians in female fertility prediction after autologous bone marrow transplantation for lymphoma? A pilot study. J Chemother 2014; 26:293-9. [PMID: 24621169 DOI: 10.1179/1973947813y.0000000162] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
OBJECTIVE(S) The report of our experience on fertility preservation and the validation of some tools useful to predict fertility in young females who underwent haematopoietic cell transplantation for their lymphoma. STUDY DESIGN A retrospective study involving 17 consecutive women of child-bearing age affected by lymphoma and submitted to haematopoietic cell transplantation in our centre. RESULTS We described a high rate of parenthood in our patient series: 5 out of 17 (29%) patients became pregnant and 1 out of 5 had two pregnancies. It is suggestive that only patients who received gonadotropin-releasing hormone (GnRH) analogues co-treatment conceaved. Antral follicles number or ovarian volume, ascertained through transvaginal ultrasound before starting treatment, more than anti-Mullerian hormone (AMH) value, are tools that may help physicians to better predict fertility in young females of child-bearing age affected by lymphoma who desire to get pregnant after cancer cares. CONCLUSION(S) The high rate of maternity we recorded may lead to comfort the young women who hope to become pregnant after cancer cares because pregnancy is possible in a certain percentage of cases even after highly toxic treatments to the ovaries. A higher ovarian volume or a higher number of antral follicles, before treatment start, ensures a greater chance of successful pregnancies. AMH value in lymphoma survivors is not sufficient to guide physicians in fertility predictions.
Collapse
|
14
|
Furlan C, Michieli M, Bortolus R, Mascarin M, Avanzo M, Rupolo M, Zanet E, Trovo M. EP-1059: Radiotherapy after autologous self cell transplant in Hodgkin lymphoma: better outcome for isolated recurrence. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31177-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
15
|
Zanet E, Manuele R, Michieli M, Rupolo M, Berretta M, Florio F, Basaglia G, Camporese A, Tirelli U. Mycobacterium tuberculosis:An Infection We Should Suspect in Bone Marrow Transplantation. J Chemother 2013; 23:312-3. [DOI: 10.1179/joc.2011.23.5.312] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
16
|
Berretta M, Martellotta F, Simonelli C, Di Benedetto F, De Ruvo N, Drigo A, Bearz A, Spina M, Zanet E, Berretta S, Tirelli U. Cetuximab/Targeted Chemotherapy in an HIV-Positive Patient with Metastatic Colorectal Cancer in the HAART Era: a Case Report. J Chemother 2013; 19:343-6. [PMID: 17594933 DOI: 10.1179/joc.2007.19.3.343] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Recent data have shown the efficacy of cetuximab/Folfiri regimen in patients with chemotherapy-resistant metastatic colorectal cancer. In the literature there are no data about this treatment in HIV-positive patients with metastatic colorectal cancer. At the Aviano Cancer Center, we used the cetuximab/Folfiri regimen and concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. The patient experienced acceptable non-hematological toxicity, without any opportunistic infection and his HIV infection was kept under control. This case suggests that, in the HAART era, a multidisciplinary approach can be offered to HIV patients with advanced cancer when they have good performance status, resulting in efficacious control of the HIV infection.
Collapse
Affiliation(s)
- M Berretta
- Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Berretta M, Zanet E, Nasti G, Lleshi A, Frustaci S, Fiorica F, Bearz A, Talamini R, Lestuzzi C, Lazzarini R, Fisichella R, Cannizzaro R, Iaffaioli RV, Berretta S, Tirelli U. Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC). Arch Gerontol Geriatr 2011; 55:271-5. [PMID: 21937127 DOI: 10.1016/j.archger.2011.08.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Revised: 08/22/2011] [Accepted: 08/23/2011] [Indexed: 12/23/2022]
Abstract
Elderly patients constitute a subpopulation with special clinical features that differ from those of the general population and are under-represented in clinical trials. We retrospectively analyzed the toxicity and efficacy of oxaliplatin-based chemotherapy in the treatment of elderly patients affected by metastatic (m) CRC. Seventy-five consecutive patients aged 65-75 years (median age 71 years), 51 males and 24 females, with mCRC and measurable disease, were analyzed. The primary site of metastases was the liver (38.6% of patients). The majority of patients had a performance status (PS) according to the Eastern Cooperative Oncology Group (ECOG) PS before treatment of 0-1 (96%). The overall response rate was 57.3%, median progression-free survival was 7 months and median overall survival was 27 months. The main hematological and extra-hematological toxicities (grade 3 or 4) were neutropenia (20.0%), and neurological toxicity or diarrhea (6.7%), respectively. No toxic death occurred. Oxaliplatin-based chemotherapy maintains its efficacy, and safety in elderly patients with mCRC and good PS. This regimen should be considered in the treatment of this particular setting of patients.
Collapse
Affiliation(s)
- Massimiliano Berretta
- Department of Medical Oncology, National Cancer Institute, IRCCS, Via Franco Gallini 2, I-33081 Aviano (PN), Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Cappellani A, Di Vita M, Lo Menzo E, Zanghì A, Lanzafame S, Veroux P, Zanet E, Cavallaro A, Berretta M. Muscular metastasis from mesocolic and duodenal leiomyosarcoma. A case report and a review of the literature. Ann Ital Chir 2011; 82:383-387. [PMID: 21988046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND Mesenteric and duodenal leiomyosarcomas are very rare malignancies. Muscular metastases from leiomyosarcoma are even more rare. Surgery is the only chance of cure and should be attempted whenever possible. The relief of symptoms and the prevention of recurrences are ultimately the aims of surgery. We present a unique case of mesocolic and duodenal leiomyosarcoma with muscular metastases. CASE REPORT A 61 year old woman was treated by radical resection including left neftectomy and left hemicolectomy for a leiomyosarcoma of the left mesocolon. Three years after the first surgery a leiomyosarcoma of the duodenal wall was diagnosed. Following a careful evaluation that ruled out the presence of other secondary locations, she underwent pancreatoduodenectomy. Three months later she observed a small, mildly painful swelling in the left thigh, rapidly growing to a diameter of 4 cm over a month period. The MRI showed a low-signal intensity malignancy in T2-weighted images whereas the lesion was homogeneously enhanced by Gadolinium on T1-weighted imaging. The histological examination after excision confirmed the clinical suspicion of a metastasis from high grade leiomyosarcoma. Successively the patient underwent a palliative chemotherapy treatment with epirubicin and ifosfamide for three cycles. The patient experienced a progression of disease with multiple pulmonary and encephalic metastases five months later. CONCLUSION Muscular metastases from leiomyosarcoma are occasionally described in the literature. The apparition of muscular metastases is considered a negative prognostic factor and shortly precedes massive distant diffusion of the malignancy. Denervation syndrome can be a risk factor for muscular metastases. To our knowledge, this is the first report of a skeletal-muscle metastasis following mesenteric and duodenal leiomyosarcoma.
Collapse
|
19
|
Giacalone A, Lleshi A, Zanet E, Tirelli U. Symptom burden in cancer survivors 1 year after diagnosis. Cancer 2011; 118:1955; author reply 1955-6. [DOI: 10.1002/cncr.26443] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
20
|
Zanet E, Berretta M, Martellotta F, Cacopardo B, Fisichella R, Tavio M, Berretta S, Tirelli U. Anal cancer: Focus on HIV-positive patients in the HAART-era. Curr HIV Res 2011; 9:70-81. [PMID: 21410431 DOI: 10.2174/157016211795569087] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2010] [Accepted: 03/03/2011] [Indexed: 12/12/2022]
Abstract
Anal cancer represents an increasing health problem, especially in immune-compromised patients, as HIV-positive patients. Notably, a significant higher incidence rate is reported among HIV infected patients with the advent of highly active antiretroviral therapy (HAART). To date, no randomised trial supports the correlation between existing screening strategies and reduced progression of anal intraepithelial neoplasia (AIN) to anal cancer or improved survival. Nevertheless, screening and treatment of AIN by topical agents should be implemented in high risk population. Data on invasive anal cancer treatment show that combined modality treatment (CMT) is the treatment of choice. Early reports on HIV-positive patients describe higher treatment toxicity and a relation with lower CD4 count and higher HIV viral load. More recently, reported outcomes seem to be similar in HIV-positive population and general population. Reports on a rise in local recurrence rates and in acute side effects along with a correlation with pre-treatment CD4 counts in HIV-positive patients, are not confirmed by all authors. The development of the first approved vaccine is a milestone in the field of anogenital cancers. However, many questions are still unresolved especially as concerns immunization in the setting of HIV infection.
Collapse
Affiliation(s)
- Ernesto Zanet
- Department of Surgery, University of Catania, Via S. Sofia, 180, 95100 Catania, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Fiorica F, Berretta M, Colosimo C, Stefanelli A, Ursino S, Zanet E, Palmucci T, Maugeri D, Malaguarnera M, Palmucci S, Grasso M, Tirelli U, Cartei F. Glioblastoma in elderly patients: Safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 2010; 51:31-5. [DOI: 10.1016/j.archger.2009.06.011] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2009] [Revised: 06/22/2009] [Accepted: 06/26/2009] [Indexed: 10/20/2022]
|
22
|
Spina M, Chimienti E, Martellotta F, Vaccher E, Berretta M, Zanet E, Lleshi A, Canzonieri V, Bulian P, Tirelli U. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2010; 116:1495-501. [PMID: 20108270 DOI: 10.1002/cncr.24922] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND Patients with aggressive non-Hodgkin lymphoma (NHL) develop central nervous system (CNS) progression or recurrence during the course of their disease. Patients with human immunodeficiency virus (HIV)-NHL often develop CNS progression despite the use of prophylaxis. Liposomal cytarabine (DepoCyte) has shown activity in lymphomatous meningitis, but there are limited data for prophylaxis. METHODS Between May 2006 and December 2008, a phase 2 study of intrathecal liposomal cytarabine was performed at the dose of 50 mg in 30 patients with HIV-NHL, with the aim of evaluating feasibility and activity for prophylaxis. RESULTS Liposomal cytarabine was well tolerated, with headache grade I to III being the most frequent side effect in 40% of patients. With a median follow-up of 10.5 months, only 1 (3%) patient developed a combined systemic and meningeal recurrence. The use of liposomal cytarabine allowed significant reduction of the number of lumbar injections in comparison to the standard schedules (around 50%), improving the quality of life of patients and reducing the professional exposure risk. CONCLUSIONS In this first study on prophylaxis of lymphomatous meningitis in HIV-NHL, liposomal cytarabine seems safe and active; it reduces by approximately 50% the number of lumbar punctures, and exposure risk for health staff as well.
Collapse
Affiliation(s)
- Michele Spina
- Division of Medical Oncology A, National Cancer Institute, Via Franco Gallini 2, 33081-Aviano (PN) Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Berretta M, Zanet E, Basile F, Ridolfo AL, Di Benedetto F, Bearz A, Berretta S, Nasti G, Tirelli U. HIV-positive patients with liver metastases from colorectal cancer deserve the same therapeutic approach as the general population. ACTA ACUST UNITED AC 2010; 33:203-4. [PMID: 20389148 DOI: 10.1159/000292126] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
24
|
Fiorica F, Cartei F, Ursino S, Stefanelli A, Zagatti Y, Berretta S, Figura S, Maugeri D, Zanet E, Spartà D, La Morella C, Tirelli U, Berretta M. Safety and feasibility of radiotherapy treatment in elderly non-small-cell lung cancer (NSCLC) patients. Arch Gerontol Geriatr 2010; 50:185-91. [DOI: 10.1016/j.archger.2009.03.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2008] [Revised: 03/19/2009] [Accepted: 03/22/2009] [Indexed: 01/02/2023]
|
25
|
Martellotta F, Berretta M, Vaccher E, Schioppa O, Zanet E, Tirelli U. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2010; 7:634-8. [PMID: 19929800 DOI: 10.2174/157016209789973619] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
In the HAART era Kaposi's sarcoma (KS) remains the second most frequent tumor in HIV-infected patients worldwide, and it has become the most common cancer in Sub-Saharan Africa. In western countries the risk for KS in men having sex with men (MSM) is 5 to 10 times higher compared to other groups of individuals practicing other HIV-risk behaviors. Patients with KS in Sub-Saharan Africa have very high tumor burdens and rapid disease progression with a diminished life expectancy of less than 6 months. KS lesions are comprised of both distinctive spindle cells of endothelial origin and a variable inflammatory infiltrate, which suggests that KS may result from reactive hyperproliferation induced by chronic inflammation, and therefore it is not a true neoplasm. KS has a variable clinical course ranging from very indolent forms, requiring no or minimal therapy, to a rapidly progressive disease. Treatment decisions must take into consideration the extent and the rate of tumor growth, patient's symptoms, immune system conditions and concurrent HIV-related complications. Several different therapeutic options are available but the optimal therapy is still unclear. Highly Active Antiretroviral Therapy (HAART) including protease inhibitors (PI) may represent the first treatment step for slowly progressive disease; chemotherapy (CT) plus HAART is indicated for visceral and/or rapidly progressive disease, whereas maintenance (M)-HAART after systemic chemotherapy may be an effective anti-KS measure after debulking CT. The angiogenic nature of KS makes it particularly suitable for therapies based on targeted agents such as metalloproteinase inhibitors, angiogenesis inhibitors and tyrosine kinase inhibitors. The aim of this article is to provide an up-to-date review of the current status and perspectives of AIDS-related KS in the HAART era.
Collapse
|
26
|
Cappellani A, Zanghi A, Di Vita M, Zanet E, Veroux P, Cacopardo B, Cavallaro A, Piccolo G, Lo Menzo E, Murabito P, Berretta M. Clinical and biological markers in gastric cancer: update and perspectives. Front Biosci (Schol Ed) 2010; 2:403-12. [PMID: 20036956 DOI: 10.2741/s73] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Gastric cancer is the second cause of death from cancer worldwide and the only chance to reach better outcomes lays on an early diagnosis. The need for non-invasive, low-cost tests is invoked also in countries in which imaging and endoscopic screening have already showed the ability to improve early diagnosis and overall survival. Genomic medicine could allow a better understanding of regulatory pathways driving the development and growth of gastric cancer and the characterization of specific molecular targets actually stimulate new drug developments. The knowledge of the role of Helicobacter pylori (HP) in gastric tumor pathogenesis has put new insides in the understanding of this peculiar disease and enriched the field of gastric biomarkers.
Collapse
Affiliation(s)
- Alessandro Cappellani
- Department of Surgery, General and Breast Surgery Unit, University of Catania, University Hospital of Catania, Catania, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Berretta M, Zanet E, Taibi R, Martellotta F, Pavone P, Bearz A, Gobitti C, Ciancia EM, Canzonieri V, Tirelli U. Leiomyosarcoma of the parotid gland in an HIV-positive patient: therapeutic approach, clinical course and review of the literature. J Chemother 2009; 21:215-8. [PMID: 19423477 DOI: 10.1179/joc.2009.21.2.215] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Leiomyosarcoma of the parotid gland is a rare tumor with only six cases reported in the english literature. To date, the association of this rare tumor with HIV infection has never been reported. We report the first case of a 19-year-old Caribbean woman affected by leiomyosarcoma of the parotid gland and HIV infection. Surgery, radiotherapy and chemotherapy used in this patient did not provide a good result in terms of overall survival. Intercurrent disease, opportunistic infection and chemotherapy cross-reaction have not been reported during this treatment regimen. The ability to use combined modality interventions in patients with secondary malignancies and immunosuppression requires further study with focus on both tolerance and efficacy.
Collapse
Affiliation(s)
- M Berretta
- Division of Medical Oncology A, National Cancer Institute, Aviano, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Berretta M, Cappellani A, Di Benedetto F, Lleshi A, Talamini R, Canzonieri V, Zanet E, Bearz A, Nasti G, Lacchin T, Berretta S, Fisichella R, Balestreri L, Torresin A, Izzi I, Ortolani P, Tirelli U. Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study. ACTA ACUST UNITED AC 2009; 32:319-24. [PMID: 19521118 DOI: 10.1159/000215719] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Data on colorectal cancer (CRC) in HIV-positive patients are limited. The study objective was to investigate and compare clinical presentation and outcome between HIV-positive and HIV-negative CRC patients. PATIENTS AND METHODS Between September 1985 and November 2003 we identified 27 cases of HIV-positive CRC patients from the cancer registry database - Italian Cooperative Group AIDS and Tumours (GICAT); the clinical presentation/outcome information was retrieved. Each HIV-positive patient from our institution was randomly matched (ratio 1:2) with HIV-negative patients (54 controls) based on age, sex, and year of diagnosis in the same time period. Differences in clinical presentation, treatment, and overall survival were assessed. RESULTS Of 1130 HIV-negative CRC patients, 54 were identified and matched with 27 HIV-positive patients. Compared with the HIV-negative patients, the HIV-positive patients had a higher risk of lower performance status (PS: > or =2) (odds ratio (OR) = 14.4; 95% confidence interval (CI): 3.6-57.7), a higher risk of unfavorable Dukes' stage (D) (OR = 4.9; 95% CI: 1.8-13.5), and a higher risk of poor grading (G3-G4) (OR = 5.0; 95% CI: 1.9-13.4). Median overall follow-up was 27 months (range: 2-212). At multivariate analysis, the only characteristics that significantly reduced the survival of the CRC patients were: HIV-positive status (hazard ratio (HR): 2.4; 95% CI: 1.1-5.2) and Dukes' stage D (HR: 3.7; 95% CI: 1.9-7.1). CONCLUSION Our data show that HIV-positive CRC patients compared to HIV-negative patients have a poorer PS, an unfavorable Dukes' stage, higher grading and shorter survival.
Collapse
|
29
|
Berretta M, Lleshi A, Zanet E, Bearz A, Simonelli C, Fisichella R, Nasti G, Berretta S, Tirelli U. Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. ACTA ACUST UNITED AC 2008; 31:394-7. [PMID: 18596388 DOI: 10.1159/000132360] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND In the era of highly active antiretroviral therapy (HAART), malignancies are the primary cause of increased mortality in patients with human immunodeficiency virus (HIV) infection, hence representing a new challenge for oncologists. To date, there is little evidence in the English literature about chemotherapy treatment in HIV-positive patients with metastatic colorectal cancer. CASE REPORT We describe the case of an HIV-positive 48-year-old male patient with metastatic colorectal cancer, treated with a bevacizumab, irinotecan, fluorouracil, and leucovorin regimen, with concomitant HAART. No opportunistic infections and grade 3-4 haematological and non-haematological toxicity were reported. The HIV infection was kept under control during the bevacizumab chemotherapy treatment. CONCLUSIONS This case suggests that, in the HAART era, the best multidisciplinary approaches can be offered to HIV-positive patients with metastatic colorectal cancer, who have a good performance status and a well controlled HIV infection. An HIV infection should not preclude the use of the best available chemotherapy treatment in this particular group of patients, including targeted/biological drugs.
Collapse
|
30
|
Tirelli U, Berretta M, Di Benedetto F, Zanet E, Bearz A, Lleshi A, Simonelli C, Berretta S, Spartà D. Presurgical chemotherapy (CT) with FOLFOX4-regimen for patients (pts) with unresectable liver metastases (LM) from colorectal cancer (CRC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15052] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Talamini R, Polesel J, Spina M, Chimienti E, Serraino D, Zucchetto A, Zanet E, Franceschi S, Tirelli U. The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma. Int J Cancer 2008; 122:1624-9. [PMID: 18059029 DOI: 10.1002/ijc.23205] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Tobacco smoking and alcohol consumption have not been clearly related to the risk of non-Hodgkin lymphoma (NHL), and the impact of these two factors on survival of NHL patients has received little attention. Cases were 268 subjects with incident histologically-confirmed NHL, admitted as inpatients to the Division of Medical Oncology, between 1983 and 2002. These individuals were enrolled as cases in case-control studies conducted at the same institution over the same period. For all patients clinical (histological subtype, major prognostic factors and treatment) and epidemiological data (smoking and drinking habits) were available. Survival analysis was performed using Kaplan-Meier methods. Hazard ratio (HR) was estimated by Cox proportional hazard model. Compared to never smokers, patients who smoked >or=20 cigarettes/day had higher risks of death (HR = 1.70, 95% confidence interval (CI): 1.06-2.73) and lower survivals at 5 years (60 and 46%, respectively). Likewise, patients who drunk >or=4 drinks/day showed 1.69-fold higher probability of death (95% CI: 1.04-2.76) in comparison to drinkers of <2 drinks/day (5-year survival: 47 and 67%, respectively). When combining exposure to alcohol and tobacco, no excess of death emerged in light drinkers (<4 drinks/day), irrespective of their smoking habits, but higher risks of death emerged among heavy drinkers. In the present study, heavy tobacco smoking, and particularly, heavy alcohol drinking were associated with poor survival in NHL patients. Our findings strongly encourage physicians to advice NHL patients to stop smoking and diminish alcohol consumption to obtain improvements in the course of NHL.
Collapse
Affiliation(s)
- Renato Talamini
- Unit of Epidemiology and Biostatistics, National Cancer Institute, Aviano, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|